Shared molecular failure
Premature termination codons create a common translation problem across otherwise fragmented diseases.
Investors
A platform thesis.
Measured by evidence gates.
KritRNA is an early preclinical biotechnology company building suppressor-tRNA design and translation-system modelling capability from India.
Programmable modality
Suppressor tRNAs can be redesigned for selected stop codons and disease contexts.
Compounding evidence
Assay-labelled results can improve future candidate prioritisation.
Asset and platform optionality
Validated sequence families may support disease-wise licensing; computational engines may become licensable later.
Capital strategy
De-risk with grants, then raise on proof
Non-dilutive grants first
De-risk platform and assay work without forcing an early priced round.
CRO / wet-lab validation
Generate reproducible readthrough, protein, function and safety evidence.
Advance on evidence
Use experimental gates—not calendar promises—to select programmes.
Priced round after proof
Raise against validated milestones and a clearer preclinical path.
Public pages do not disclose confidential fundraising terms, unpublished candidate sequences, proprietary scoring logic or unfiled IP details.
Controlled material request
Start with fit, then move to diligence.
Investor material is shared manually after the founders review stage, mandate and strategic fit.
Review the evidence-gated programmes